Abstract
Mycobacteria expressing recombinant antigens are already being developed as vaccines against both infections and tumors. Little is known about how dendritic cells might process such antigens. Two different mycobacterial species, the fast-growingMycobacterium smegmatisand the slow-growingM. bovis M. bovisBCG, were engineered to express a model tumor antigen, the Kb-restricted dominant cytotoxic T-lymphocyte epitope OVA257-264. RecombinantM. bovisBCG but not recombinantM. smegmatisconferred protection to mice challenged with the B16-OVA tumor cell line. We went on to investigate whether the contrast in antitumor efficacy could be due to differences in how dendritic cells process antigen from the two mycobacterial strains for class I presentation. Both strains of mycobacteria caused phenotypic maturation of dendritic cells, but recombinantM. smegmatisinfection led to a greater degree of dendritic cell maturation than recombinantM. bovisBCG infection. Antigen from recombinantM. smegmatiswas processed and presented as OVA257-264on Kbmolecules by the dendritic cell line DC2.4 but not by bone marrow-derived dendritic cells (BMDC) or splenic dendritic cells. In contrast, antigen from recombinantM. bovisBCG was presented by all three dendritic cell types as long as the mycobacteria were viable. Such presentation was dependent on proteasome function and nascent major histocompatibility complex (MHC) class I molecules in DC2.4 cells but independent of the proteasome and transporter associated with antigen processings (TAP) in BMDC and splenic dendritic cells. These data demonstrate for the first time that antigen vectored by the slow-growingM. bovisBCG but not that vectored by fast-growing, readily destroyedM. smegmatisis processed and presented on MHC class I by in vitro-generated dendritic cells, which has implications for recombinant microbial vaccine development.